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Abstract
Background: Treatment options for Visceral Leishmaniasis (VL) in East Africa are far from satisfactory due to cost,
toxicity, prolonged treatment duration or emergence of parasite resistance. Hence there is a need to explore
alternative treatment protocols such as miltefosine alone or in combinations including miltefosine, sodium
stibogluconate (SSG) or liposomal amphotericin B. The aim of this trial is to identify regimen(s) which are
sufficiently promising for future trials in East Africa.
Methods/Design: A phase II randomized, parallel arm, open-labelled trial is being conducted to assess the efficacy
of each of the three regimens: liposomal amphotericin B with SSG, Liposomal amphotericin B with miltefosine and
miltefosine alone. The primary endpoint is cure at day 28 with secondary endpoint at day 210 (6 months). Initial
cure is a single composite measure based on parasitologic evaluation (bone marrow, spleen or lymph node
aspirate) and clinical assessment. Repeated interim analyses have been planned after recruitment of 15 patients in
each arm with a maximum sample size of 63 for each. These will follow group-sequential methods (the triangular
test) to identify when a regimen is inadequate (<75% efficacy) or adequate (>90% efficacy). We describe a method
to ensure consistency of the sequential analysis of day 28 cure with the non-sequential analysis of day 210 cure.
Discussion: A regimen with adequate efficacy would be a candidate for treatment of VL with reasonable costs.
The design allows repeated testing throughout the trial recruitment period while maintaining good statistical
properties (Type I & II error rates) and reducing the expected sample sizes.
Trial Registration: ClinicalTrials.gov: NCT01067443
Keywords: Visceral Leishmaniasis, Miltefosine, AmBisome®, Tri-angular test, protocol, RCT
Background
Visceral leishmaniasis (VL), or kala-azar, is the most ser-
ious of all Leishmania infections and is fatal if left
untreated [1]. A complication of VL, particularly in
Sudan, is post kala-azar dermal leishmaniasis (PKDL)
where patients have no detectable parasites in the
spleen, bone marrow or lymph nodes but develop macu-
lar and papulomacular skin lesions in which leishmania
parasites may be detected. The median time to occur-
rence of PKDL is 6 months after treatment [2].
The monotherapeutic treatment options available in
East Africa are far from satisfactory due to cost (Liposo-
mal amphotericin B
®), toxicity (sodium stibogluconate,
SSG) or prolonged treatment duration (one month,
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and possible emergence of parasite resistance. Paramo-
mycin, both in monotherapy and in combination with
SSG has just recently completed development in the
East Africa. However its use in monotherapy does not
appear realistic in the region [3,4]. This calls for
exploration of new treatment options including miltefo-
sine monotherapy and alternative combination treat-
ment algorithms combining drugs with different modes
of action like SSG, Liposomal amphotericin B
® and mil-
tefosine which could provide new treatment option with
reasonable costs due to reduction in needed dosages
and treatment duration and less risk of resistance emer-
ging [5].
Sodium stibogluconate for 30 days is currently the
mainstay of VL treatment in East Africa. Liposomal
amphotericin B
® has also been used in the field, but pri-
marily as a rescue treatment for VL. There is limited
experience of the use of miltefosine which is not regis-
t e r e di nt h er e g i o n :d a t aa r ea v a i l a b l ef r o mo n l yo n e
study, conducted in Ethiopia, which demonstrated effi-
cacy of 93% for miltefosine monotherapy at 6 months
follow-up in HIV negative patients [6]. All three drugs
h a v eb e e ns t u d i e da n da r er e g i s t e r e di nI n d i aa n da
phase IV study for miltefosine (28 day course) has been
completed [7,8]. In addition a phase-III study conducted
in India evaluated 3 short course combinations, includ-
ing Ambisome plus miltefosine for 7 days, which had a
6 month efficacy of 97% [9].
This study intends to look at potential feasible short
course combination therapies as well as evaluate and
possibly register miltefosine in its conventional dose and
regimen for VL in Sudan and Kenya. It is also intended
to supply miltefosine pharmacokinetics in VL patients in
East Africa, including children, for whom there is little
such information globally. It is a phase-II proof of con-
cept study for efficacy and safety of two potential
combinations.
Methods/Design
Study Design
A phase II open-label randomized controlled clinical
trial.
Main Objectives
To assess the efficacy of the following treatments for
primary VL at day 28:
￿ the combination of single dose Liposomal ampho-
tericin B
® and a 10 day course of SSG
￿ the combination of single dose Liposomal ampho-
tericin B
® and a 10 day course of Miltefosine
￿ a 28 day course of Miltefosine
Setting
The areas of the two trial sites are endemic for VL.
They are Dooka Hospital, Gedarif State, Sudan and
Kimalel Hospital, Baringo district, Kenya. Addition of
another Sudanese site will be considered. Data are
brought to the Data Centre based at the study’s Coordi-
nation Centre in Nairobi, Kenya. The trial is being con-
ducted by the Leishmania East Africa Platform (LEAP:
http://www.dndi.org/leap-platform) in collaboration with
the trial sites and is sponsored by the Drugs for
Neglected Diseases initiative (http://www.dndi.org).
Outcome measures
Primary outcome
The primary endpoint is initial cure, assessed at day 28
(figure 1) based on clinical assessment and parasitologic
evaluation (bone marrow or lymph node for Sudan and
bone marrow or spleen aspirate for Kenya).
Secondary outcomes
￿ Final cure, defined as the percentage of patients
cured at day 210 (6 months follow-up) based on
clinical evaluation, with parasitology done only if
clinically indicated according to a standardised clini-
cal assessment.
￿ Adverse events and serious adverse events occur-
ring in the three study arms up to day 60.
￿ Description of the pharmacodynamic properties of
all the three arms.
￿ Description of the pharmacokinetic properties of
Miltefosine alone and in combination with Liposo-
mal amphotericin B
®.
Allocation
Randomization sequences were generated, stratified by
site in pre-determined block sizes by the Data Centre.
Randomization codes have been concealed from inves-
tigators at the trial sites using sealed sequentially num-
bered, opaque envelopes. A copy of the randomization
list is securely stored at the Data Centre. The envel-
opes are numbered sequentially externally. Inside each
o n et h e r ei sar a n d o m i z a t i o ns h e e tw i t ht h es a m e
sequential number as well as the treatment allocation.
These randomization sheets are filed in the source
documents which the monitor verifies at each site visit
to confirm that only one envelope was opened for each
patient to ensure integrity of the randomization
process.
Interventions
Liposomal amphotericin B
® is being given as a single
d o s eo nd a y1a tad o s eo f1 0m g / k gb o d yw e i g h t
infused in 5% dextrose running for 1-2 hours.
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b o d yw e i g h td a i l y ,u pt oam a x i m u mo f1 5 0m g ,f o r2 8
days when used alone.
Miltefosine is being given orally at a dose of 2.5 mg/kg
b o d yw e i g h td a i l y ,u pt oam a x i m u mo f1 5 0m g ,f o r1 0
days starting on day 2 following a single dose of Liposo-
mal amphotericin B
® 10 mg/kg.
SSG is being given IV/IM at a once daily dose of 20
mg/kg body weight daily for 10 days starting on day 2
following a single dose of Liposomal amphotericin B
®.
Therefore the dose regimens is as follows
￿ Liposomal amphotericin B
® one dose of 10 mg/kg
body weight (IV) on day 1 followed by 10 days of
SSG at 20 mg/kg body weight (IV/IM) from days 2-
11.
￿ Liposomal amphotericin B
® one dose of 10 mg/kg
body weight (IV) on day 1 followed by 10 days of
miltefosine at 2.5 mg/kg body weight (oral) from
days 2-11.
￿ Monotherapy course of miltefosine at 2.5 mg/kg
body weight (oral) from days 1-28.
All failure with compliance will be documented on the
trial medication pages of the CRF.
Screening
Inclusion criteria
Patients with clinical signs of VL (fever for at least 2
weeks and splenomegaly) and diagnosis confirmed by
visualization of parasites in tissue samples on micro-
scopy, aged between 7 and 60 years inclusive, signed
written informed consent, negative HIV status.
Exclusion criteria
Patients who have received any anti-leishmanial drugs in
the last 6 months/relapse cases, negative lymph node/
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Figure 1 Consort Trial Diagram.
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Page 3 of 10bone marrow or spleen smears, severe protein and or
caloric malnutrition, previous history of hypersensitivity
reaction to SSG or Amphotericin B, suffering from con-
comitant severe infection such as TB or other serious
underlying disease which would preclude evaluation of
patients response to study medication, suffering from
other conditions associated with splenomegaly such as
schistosomiasis, previous history of cardiac arrhythmia
or an abnormal ECG, female of child bearing age (preg-
nant or lactating), haemoglobin <5 mg/dL, WBC <1 ×
10
3/mm
3, platelets <40,000/mm
3, abnormal liver func-
tion tests (ALT and AST) of more than three times the
upper limit of the normal range, serum creatinine out-
side the normal range for age and gender, major surgical
intervention within two weeks prior to enrolment. These
tests are standardised but it is not feasible to standardise
routine clinical laboratory assessments as different
machines and reagents are being used. However both
internal and external QC will be carried out at both
sites on a regular basis and training offered to site staff
at the beginning and during the trial to ensure that the
data collected are reliable and comparable.
HIV-status and VCT
All patients are offered counselling and screening for
HIV (voluntary counselling and testing programme
(VCT). This is done at the same time as consent is
obtained for inclusion in the trial. Patients who decline
VCT or are found to be HIV positive are not eligible to
participate in this trial but receive appropriate treat-
ment, according to national treatment guidelines. Addi-
tionally, they are referred onwards for treatment,
surveillance and follow up according to the national
protocol for HIV positive patients.
Consent
Standardised consent forms, adapted to the local context
and translated into local languages and approved by
ethics committees are being used. Signatures or thumb-
prints are obtained for consent, with witnesses in the
latter case (illiterate subjects) for adults. In the case of
children, the investigator gets their assent once permis-
sion of either the child’s parent or guardian has been
obtained.
Patients who do not meet inclusion criteria or who do
not give consent are offered free treatment outside the
trial, according to national treatment guidelines.
Analysis and sample size
Analysis of primary endpoint: cure at day 28
The study is designed and will be analyzed according to
group-sequential methods, specifically the triangular test
[10-12]. Following the trials main objectives, the aim of
the analysis is to efficiently identify a regimen that is a)
inadequate, so its development can be discontinued, or
b) adequate, so its development can proceed. In these
terms, the highest efficacy (i.e. percentage of patients
cured as per primary outcome) considered inadequate is
set in this trial to be 75% (denoted p0), and the lowest
efficacy considered adequate as 90% (denoted pa). The
null and alternative hypotheses are H0: p ≤ p0 and H1: p
>pa respectively.
The triangular stopping boundary, as shown in Figure
2, was defined following Ranque et al [10]. With both
type I and type II error rates set at 5% (power 95%), and
sequential analysis being done after every 15 patients
per arm, the maximum sample size required is 189 (63
per arm). The actual sample size may be less than this,
depending on when the actual percentage of patients
cured leads to a boundary being crossed. The bound-
aries were calculated using custom-written functions in
the R software [13], having checked that they could
reproduce the example in Ranque et al [10].
Each analysis consists of calculating the quantities V
(proportional to current sample size) and Z (number of
observed minus expected treatment successes) and plot-
ting them on Figure 2. Hence, for each arm, a line from
t h eo r i g i ni sp l o t t e do v e rt i m e .R e c r u i t m e n ti na na r m
will be stopped when this line crosses either boundary
of the triangular region. Crossing the lower or upper
boundary means concluding inadequacy or adequacy,
respectively. Since the three arms will be assessed sepa-
rately, it is possible that one of them may be stopped
prior to others.
The above procedure is subject to a constraint
imposed for the PK component of the trial, which
requires at least 30 patients in arms 2 and 3, subject to
efficacy not being inadequate. Therefore, if the upper
boundary is crossed at n = 15 (indicating adequate effi-
cacy) that arm will be continued regardless until n = 30.
However, if the lower boundary is crossed (indicating
inadequate efficacy) at n = 15, then it will be stopped.
Crossing a boundary of the region implies that the
percentage of patients cured is either greater than 90%
(if the upper boundary is crossed) or no more than 75%
(if the lower boundary is crossed). The maximum likeli-
hood estimate of the efficacy, i.e. the number cured
divided by the number of patients, is a biased estimator
due to the sequential nature of the trial. To take this
into account, the analysis will follow Bellissant et al [11].
First, the sample quantity C* will be calculated as θ2
aV∗,
where V* is the terminal value of V from the data sam-
ple, and the θa parameter is the log-odds ratio θ =l o g e
(p(1- p0)/p0(1- p)) for p = pa. Then, the tables in White-
head’s Appendix A [12] will be used to obtain the signif-
icance level of the test, and point and interval estimates
of p. The latter are provided in terms of factors by
which to multiply θa. Finally, these three values of θ (i.e.
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will be transformed to corresponding sample values of p
by p =( p0e
θ)/(1+ p0(e
θ-1)). Analysis will be done using
STATA [14].
Analysis of secondary endpoint: cure at day 210
The sequential analysis described above relates only to
efficacy on day 28, not day 210. However, because the
latter is likely to be highly correlated with the former,
ignoring the sequential design in the latter analysis
could give inconsistent results. For example, if the status
of all patients is the same at day 210 as at day 28, then
using different methods for analysis would give different
efficacy estimates from the same data. This is because
the day 28 estimate takes into account the sequential
design which, in general, would differ from conventional
analysis done on the same data at day 210.
Therefore, the day 210 efficacy will be estimated by
considering it in terms of events over two consecutive
time periods: up to day 28, and from day 28 to day 210.
More specifically, the day 210 efficacy (i.e. percentage
cured or p210)w i l lb ec o n s i d e r e da st h es u mo ft w o
probabilities, as follows:
i) probability of being cured at day 28 and remaining
cured at day 210.
ii) probability of not being cured at day 28 but
becoming cured at day 210.
Each of these probabilities is the product of two terms
and enables a point estimate of p210:
p210 = p28r + (1 − p28)s
where:
r is the percentage of those people cured at day 28
who remain cured at day 210.
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Figure 2 Triangular region for study arms. Showing the boundaries for analyzing the sequential trial using the Triangular test with the
following parameters (p0 = 0.75, pa = 0.9, a = 0.05, b = 0.05, and n = 10). The vertical line at n = 30 indicates that, for the PK component of
the trial, a minimum of 30 patients per arm will be recruited, unless the lower boundary has been crossed before then.
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Page 5 of 10s is the percentage of those people not cured at day
28 who become cured at day 210.
The confidence interval will be estimated via the sam-
pling variance of p210. Using the ‘delta method’ [15], this
can be estimated as a function of the sampling variances
of p28, r and s; these three quantities being statistically
independent. The sampling variance of p28 will be esti-
mated as the square of its standard error, which in turn
will be estimated as the width of its 95% confidence
interval divided by 2 × 1.96, using a normal approxima-
tion. The sampling variances of r and s will be estimated
by considering them as standard binomial proportions.
The above procedure ensures that, for example, if no
patients change cure status between day 28 and day 210
then the point estimates of p28 and p210 will be equal
(because r = 1 and s = 0). The confidence intervals will,
however, generally be unequal. This is because treating
the progress between day 28 and day 210 as a separate
variable implies additional sampling variation. For exam-
ple, r has sampling variation even when equal to 1.
Moreover, sampling variation is considered on the prob-
ability scale, not the log-odds scale as for p28.T h i sa l s o
means that the calculated confidence interval could
exceed the interval 0-1. In this case, it will be truncated
at the limits of that interval.
When the analysis results in an arm being stopped,
the final cure rate (day 210) will also be evaluated
(when all those patients have reached that time point).
If the point estimate of the day 210 cure rate is found
to be <90%, then the arm (arm 1 & 2) will not be con-
sidered for further study (e.g phase 3).
Within each arm, the percentage cured at each time
point will be presented by site. Chi-squared or Fisher’s
exact tests will be used to test for differences between
sites in terms of primary and secondary efficacy end-
points at the 5% level of significance.
Schedule of Assessments and Expected Side Effects
Assessments are timed at days 0, 3, 7, 14, 21, 28, 60 and
210 (Table 1) and include clinical, parasitology, haema-
tology, biochemistry and pharmacokinetic assessments
(table 1). Baseline assessments include anthropometric,
clinical and lab evaluations. Day 60 and 210 assessments
require some flexibility on dates due to patient travel,
visit windows for each is as follows- day 60 (+/- 10
days) and day 210 (+/- 21 days).
Rescue medication
The decision to give rescue medication is based on a
standard guideline for all trial sites. Any patient who
receives rescue medication is considered a treatment
failure at initial cure if receipt of rescue occurs on or
prior to initial cure (day 28) and treatment failure at
final cure if it occurs on or prior to final cure (day
210).
Rescue treatment to be given includes:
- Liposomal amphotericin B 30 mg/kg IV split into
multiple doses (according to country protocol: Sudan -
3 mg/kg/day for 10 days)
- SSG 20 mg/kg IM for 30-60+ days: for patients not
responding to initial rescue treatment or for patients
requiring treatment for severe PKDL.
Post Kala-azar Dermal Leishmaniasis (PKDL)
A complication of Visceral Leishmaniasis, particularly in
Sudan is post-Kala-azar Dermal Leishmaniasis (PKDL).
PKDL is characterised by skin lesions which normally
occur in the months following treatment in people who
have recovered from VL. Patients are being monitored
closely for PKDL at days 0, 28, 60 and 210. Diagnosis
will be made clinically, based on the typical appearance
and distribution of the rash.
Concomitant Medication
Concomitant medication necessary for the health of the
patient is permitted during the course of the study.
Details of all concomitant medication taken during the
study are recorded in the CRF with indication, daily
dose, route and dates of administration.
Ancillary Studies
Pharmacokinetics
The effects of VL disease and geographical differences
on the pharmacokinetics (PK) of miltefosine remain lar-
gely unknown, with most available PK data coming
from a relatively healthy European patient group with
cutaneous leishmaniasis (CL) [16]. A thorough PK study
of miltefosine in adult VL patients has not been pub-
lished, let alone in paediatric patients and no such data
are available from the East-African region. This study
will describe the pharmacokinetic profile of miltefosine
in adults and children (>7 years of age) in both the
monotherapy and combination therapy arm. Any signifi-
cant PK interactions between liposomal amphotericin B
and miltefosine will be assessed in the combination
treatment arm.
Bioanalysis of miltefosine will be done on plasma sam-
p l e sw i t hav o l u m eo f5 0t o2 5 0μL taken during both
treatment and follow-up (see table 1), using a validated
liquid chromatography tandem mass spectrometry (LC-
MS/MS) assay for miltefosine [17]. In children, a more
sparse sampling strategy will be applied because of ethi-
cal concerns.
The PK of miltefosine will be modelled and analyzed
using a population PK approach, which enables, for
example the estimation of within- and between-subject
variations. Non-linear mixed-effects modelling will be
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package [18]. The minimal value of the objective func-
tion (equal to minus twice the log likelihood) provided
by NONMEM will be used as a goodness-of-fit charac-
teristic, in addition to comparisons of standard errors of
parameter estimates. Furthermore, performance of the
models will be assessed via standard goodness-of-fit
plots. Covariate models for body size will be evaluated
stepwise to explain possible differences between paedia-
tric and adult patients, including allometric or linear
scaling of clearance and volume of distribution by either
body weight or fat-free mass. The appropriateness of the
covariate model will be evaluated by comparison of the
objective function value given by NONMEM and result-
ing reduction in unexplained between-subject variability
of the respective pharmacokinetic variables.
Pharmacodynamics
To assess treatment response during and after treat-
ment, this study will apply repeated measurements of
blood parasite loads using a real time reverse
Table 1 Schedule of events
SCHEDULE OF EVENTS
Protocol Activities and Forms to Be
Completed
Screening
(day)
Treatment (day) At Follow-up
after day 30
1
-2 -3 4 5 6 7 21 Day 60 Day
210
Consent form &
XX X X X X
X XX
2
rK39 dipstick X
ECG X X X
XX X X
XX X X X
XX X X
XX X X X X
XX X X XXX X X X
X
XX X X XXX X X X
XXX X X XXX X X X X XX X X
PK study for Miltefosine - Arm 2 -
Adults5
X
6 XX X X X
PK study for Miltefosine - Arm 2 -
Children5
X
6 XX X X
PK study for Miltefosine - Arm 3 -
Adults5
X
6 XX X X X X X
PK study for Miltefosine - Arm 3 -
Children5
X
6 XX X X X
Volume of blood (ml) taken from Group
2 - children
7.5 2.5 2.5 10.5 0.5 10 7.5 7.5 7.5
Volume of blood (ml) taken from Group
3 - children
7.5 2.5 2.5 10.5 10.5 8 7.5 7.5
1 Patients assessment between day 60 and 210 in the event of any medical problems. Blood count, biochemistry, liver function tests parasitology and PK analysis
will be done in the event of such a visit. At the day 210 visit, flexibility (of +/- 30 days) will be allowed for timing due to practical difficulties patients may face to
meet exact timing of visits.
2 Parasitology will be done in the follow up period after day 28 if clinically indicated (i.e. if reappearance of symptoms and signs of VL).
3 2.5 ml of EDTA blood for Complete blood count; and only 0.2 ml EDTA blood used for PCR
4 7.5 ml blood for urea, creatinine, liver function test.
5 The PK study will be done on the specified days with 2.5 ml of EDTA blood taken before/after and 0.5 ml during treatment (the possible use of dried blood
spots is currently under investigation).
6 On first day of Miltefosine treatment, blood samples will be drawn 3 times: just prior to first dose, 4 & 8 hours post-dose to assess the absorption-phaseo f
miltefosine (total volume needed 2.5 ml).
Volumes of blood required for children are shown in bottom two rows. In total, 41.5 ml are required in the first 1 month during admission in group 3 and 41 ml
for group 2.
Clinical assessments will include pulse, blood pressure, temperature, weight, height (done only at baseline), spleen size, liver size.
Omollo et al. Trials 2011, 12:166
http://www.trialsjournal.com/content/12/1/166
Page 7 of 10transcriptase polymerase chain reaction (qPCR) for L.
donovani in EDTA blood based on the amplification of
single-stranded 18S rRNA as a pharmacodynamic (PD)
marker [19,20]. Differences in parasite clearance in the
blood are to be expected between the treatment arms:
combinations are likely to result in a more rapid elimi-
nation of Leishmania parasites, hence the decreased
duration of treatment. In this trial the blood parasite
counts will be used as a PD marker of the parasite clear-
ance rate and thus response to treatment.
In the arms receiving miltefosine, the outcome and para-
site clearance measured by qPCR will be linked to miltefo-
sine PK. Modelling of miltefosine PK/PD in our patients
will enable us to establish variability in pharmacokinetics
in relation to outcome, which is an essential component in
the development of new treatment regimens.
Training
All trial site staff; physicians, nurses, laboratory techni-
cians and pharmacists received training on the study
protocol, study specific procedures and International
conference on harmonisation-good clinical practise
(ICH-GCP) guidelines [21,22]. Additional training ses-
sions will be provided as required, using external con-
sultants where necessary. Documentation of receipt of
training is maintained at the Coordination Centre.
Quality control and quality assurance
Suitably qualified Clinical Monitors trained in GCP reg-
ularly visit trial sites to monitor all aspects of the trial
including; informed consent procedures, drug account-
ability, source data verification, adverse event reporting,
sample handling, analysis and secure data storage.
Data collection and data management
Data are to be recorded on 3-part no carbon required
(NCR) case report forms (CRFs) by site investigators,
transcribed from hospital source data. Unique patient
identifiers, assigned at the time of randomisation, are
linked to unique hospital record numbers. During moni-
toring visits, CRF data are cross-checked against hospital
source data as much as possible by the monitor. The
top sheet for each page of the CRF is brought to the
central Data Centre for double-entry into GCP compli-
ant open-access database software OpenClinica, version
2.7 [23] with range checks implemented to detect unu-
sual values at data entry, before analysis. Following vali-
dation, data will be read into Stata, version 11 special
edition [14] and pre-programmed command files will be
used to generate lists of data value queries in a thorough
data cross-checking process. Query forms are to be
automatically generated via Microsoft Access
© database
software and emailed to trial sites, copied to clinical
monitors. The sites will print and make resolutions. At
the next monitoring visit, monitors will verify resolu-
tions and deliver to the Data Centre. Data corrections
will be programmed in Stata to complete the data clean-
ing audit trail. At analysis, any unusual values detected
would be verified with the investigator at the sites
before final analysis is done to confirm correctness/com-
pleteness. This will also be captured in the data manage-
ment report prior to database lock.
Publication policy
DNDi, as sponsor, will render all necessary assistance to
investigators to ensure timely publication of results in
an international peer-reviewed, for the benefit of
patients and to inform national decision-making on VL
treatment guidelines. Ancillary studies will acknowledge
those involved by name where appropriate.
Confidentiality
Trial site records will contain names and residential
information for each patient to allow follow-up to take
place. Only the unique numeric identifier assigned to
patients will be extracted from patient records and
transferred to the Data Centre. Patient data will be kept
securely at trial sites under the responsibility of the site
investigator.
Audit
During the course of the trial, site audits will be under-
taken to assess compliance with ICH-GCP guidelines.
Specific issues to be assessed include adherence to the
protocol and standard operational procedures (SOPs),
consent, laboratory practise, documentation and record
keeping. All areas of non-compliance will be addressed
by the site investigators or trial coordination centre
depending on the findings.
Termination of the study
On approaching the end of planned recruitment, the trial
coordination office will send written instructions by email
to each site regarding the date to cease recruitment. All
patients will be followed up as per the protocol, with the
data being collected and cleaned. Once the data lock has
been completed, site close out visits will be performed by
the coordination team and clinical monitors. A decision for
premature termination will be taken in consultation and
agreement with the sponsor, investigators and the DSMB.
All relevant ethics committees and regulatory authorities
will also be informed of the reason for termination. Trial
master files and completed CRFs will be archived by the
coordination centre in Nairobi for 15 years.
Dissemination of Results
After recruiting 15 patients per arm, a brief interim ana-
lysis report presenting the efficacy, including the
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Monitoring Board (DSMB) whose composition is based
on WHO-TDR guidelines [24]. The DSMB membership
includes a pharmacologist, paediatrician and an epide-
miologist. The DSMB will seek advice from an external
statistician when necessary. This report will also contain
a listing of serious adverse events occurring prior to the
analysis date. Adverse event listings are to be provided
at the request of the DSMB. The DSMB, through the
Chair may request additional efficacy and safety data if
they have concerns relating to trial conduct or other
ethical and safety issues.
At the end of the trial, the clinical study report will be
circulated to Principal Investigators, DSMB, Ethics
Committees and Ministries of Health.
Ethical Approval
Ethical approval has been obtained from National and
local Ethics Committees in Kenya and Sudan prior to
the start of the trial in each Country. Ethical approval
has also been granted by LSHTM Ethics Committee, the
AMC Medical Ethics Committee issued a ‘declaration of
no objection’.
Organisation
The DNDi Coordination Team, based mainly at the
Coordination Centre, DNDi Africa, Kenya Medical
Research Institute, Nairobi, are responsible for collation
and submission of protocol amendments, organisation
of training for trial staff, monitoring and supervision of
trial conduct, day to day management of the trial, har-
vesting data collected at each site, trial monitoring visits
and data management, all to GCP standards.
Discussion
Due to limitations of current treatments, and the risk of
drug resistance developing, there is an urgent need to
develop short course combination treatments against VL
in the East Africa region. The aim of this trial is to eval-
uate potential combinations that can then be evaluated
in a large multi centre phase-III clinical trial in the
region. The current trial also aims to collect additional
data to assist in the registration of miltefosine in the
region. For this reason, three separate arms with no
between-arm comparisons were chosen and a PK/PD
component focusing on the miltefosine treatments
included. Due to potential geographical differences in
drug response within the region, the trial aims to evalu-
ate treatment in two sites: one from the northern part
(Sudan) and one from the Southern part (Kenya) of the
East African foci [3]. To make efficiencies in develop-
ment, cost and time, the study design used the triangu-
lar test. This also meant that the primary endpoint of
day 28 was selected, since a long follow up time
precludes the optimal use of such triangular tests. The
design also used the experience of a phase-II trial of
combinations conducted in India [25]. Important poten-
tial outcomes of this study include not only the registra-
tion of miltefosine in the region, and the identification
of drug combinations for phase III development, but
also the validation of a design that could be used in the
drug development process of future new chemical enti-
ties against VL.
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